+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Middle East Cell and Gene Therapy CDMO Market Forecast to 2033

  • PDF Icon

    Report

  • 150 Pages
  • October 2025
  • Region: Middle East
  • Grand View Research
  • ID: 6189463
REQUEST CUSTOMIZATION
Description Jump to:
The Middle East cell and gene therapy CDMO market size was estimated at USD 55.68 million in 2024 and is projected to reach USD 184.18 million by 2033, growing at a CAGR of 14.23% from 2025 to 2033. The market is driven due to several factors, including rising investments in advanced therapeutics, increasing prevalence of genetic disorders, increasing government support for biotech innovation, and the growing need for specialized manufacturing services.

The market is primarily driven due to the region’s growing focus on biotechnology innovation and the rising demand for personalize and advanced therapeutic solutions. Governments across the region, mainly the UAE and Saudi Arabia, are actively investing in life sciences and precision medicine as part of their national development visions (Saudi Vision 2030). Thus, these factors have led to the creation of biotech hubs, innovation zones, and public-private partnerships, which are significantly boosting local capabilities in contract development and manufacturing. Moreover, the increasing cases of rare genetic disorders and cancers in the region are also one of the factors that are prompting both local and international biotech firms to outsource complex manufacturing processes to contract development and manufacturing organizations (CDMOs) specializing in gene-modified therapies, viral vector production, and cell engineering.

Furthermore, increasing strategic collaborations between regional healthcare systems and global pharmaceutical and biotech companies are also contributing to market growth. Several companies are tapping into the region's untapped market and are forming alliances with local CDMOs and research institutions to facilitate clinical development, scale-up production, and market entry. Moreover, regional regulatory authorities are making considerable initiatives to streamline approval processes for advanced therapies, establish centralized frameworks for clinical trials, and ensure GMP-compliant manufacturing environments. Thus, these factors are further fueling market growth.

Middle East Cell And Gene Therapy CDMO Market Report Segmentation

This report forecasts revenue growth at regional levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Middle East Cell and Gene Therapy CDMO market report based on phase, product, indication, and country.

Phase Outlook (Revenue, USD Million, 2021-2033)

  • Pre-clinical
  • Clinical

Product Outlook (Revenue, USD Million, 2021-2033)

  • Gene Therapy
  • Gene-Modified Cell Therapy
  • Cell Therapy

Indication Outlook (Revenue, USD Million, 2021-2033)

  • Oncology
  • Infectious Diseases
  • Neurological disorders
  • Rare Diseases
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • Middle East

Why You Should Buy This Report

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

Report Deliverables

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Value chain based analysis (Model 2)
1.7.3. Multivariate Analysis (Model 3)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Middle East Cell and Gene Therapy CDMO Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Middle East Cell and Gene Therapy CDMO Market Dynamics
3.2.1. Market Driver Impact Analysis
3.2.2. Market Restraint Analysis
3.3. Technological Landscape
3.4. Pricing Model Analysis
3.5. Middle East Cell and Gene Therapy CDMO Market: Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
Chapter 4. Middle East Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Middle East Cell and Gene Therapy CDMO Market Phase Movement Analysis
4.3. Middle East Cell and Gene Therapy CDMO Market Size & Trend Analysis, by Phase, 2021 to 2033 (USD Million)
4.4. Pre-clinical
4.4.1. Pre-clinical Market Estimates and Forecasts, 2021-2033 (USD million)
4.5. Clinical
4.5.1. Clinical Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 5. Middle East Cell and Gene Therapy CDMO Market: Product Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Middle East Cell and Gene Therapy CDMO Market Product Movement Analysis
5.3. Middle East Cell and Gene Therapy CDMO Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
5.4. Gene Therapy
5.4.1. Gene Therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.4.2. Ex-vivo
5.4.2.1. Ex-vivo Market Estimates and Forecasts, 2021-2033 (USD Million)
5.4.3. in-vivo
5.4.3.1. in-vivo Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5. Gene-Modified Cell Therapy
5.5.1. Gene-Modified Cell Therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.2. CAR T-cell therapies
5.5.2.1. CAR T-cell therapies Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.3. CAR-NK cell therapy
5.5.3.1. CAR-NK cell therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.4. TCR-T cell therapy
5.5.4.1. TCR-T cell therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
5.5.5. Other
5.5.5.1. Other Market Estimates and Forecasts, 2021-2033 (USD Million)
5.6. Cell Therapy
5.6.1. Cell Therapy Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 6. Middle East Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Middle East Cell and Gene Therapy CDMO Market Indication Movement Analysis
6.3. Middle East Cell and Gene Therapy CDMO Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts, 2021-2033 (USD Million)
6.5. Infectious Diseases
6.5.1. Infectious Diseases Market Estimates and Forecasts, 2021-2033 (USD Million)
6.6. Neurological disorders
6.6.1. Neurological disorders Market Estimates and Forecasts, 2021-2033 (USD Million)
6.7. Rare Diseases
6.7.1. Rare Diseases Market Estimates and Forecasts, 2021-2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 7. Middle East Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis by Service, Model Type, End Use
7.1. Regional Market Dashboard
7.2. Middle East Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
7.4. Saudi Arabia
7.4.1. Key Country Dynamics
7.4.2. Competitive Scenario
7.4.3. Regulatory Framework
7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. UAE
7.5.1. Key Country Dynamics
7.5.2. Competitive Scenario
7.5.3. Regulatory Framework
7.5.4. UAE Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Kuwait
7.6.1. Key Country Dynamics
7.6.2. Competitive Scenario
7.6.3. Regulatory Framework
7.6.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Oman
7.7.1. Key Country Dynamics
7.7.2. Competitive Scenario
7.7.3. Regulatory Framework
7.7.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. Qatar
7.8.1. Key Country Dynamics
7.8.2. Competitive Scenario
7.8.3. Regulatory Framework
7.8.4. Kuwait Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Middle East Cell and Gene Therapy CDMO Market Position Analysis, 2024
8.3. Company Profiles
8.3.1. Porton Pharma Solutions, Ltd. (Porton Advanced)
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. WuXi AppTec
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Thermo Fisher Scientific, Inc.
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Charles River Laboratories
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Lonza
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. AGC Biologics
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Catalent Inc.
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Samsung Biologics
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. OmniaBio
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Rentschler Biopharma SE
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 Middle East Cell and Gene Therapy CDMO Market estimates and forecasts, by region, 2021-2033 (USD Million)
Table 3 Middle East Cell and Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 4 Middle East Cell and Gene Therapy CDMO Market estimates and forecasts, by product, 2021-2033 (USD Million)
Table 5 Middle East Cell and Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 6 Saudi Arabia Cell and Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 7 Saudi Arabia Cell and Gene Therapy CDMO Market estimates and forecasts, by product, 2021-2033 (USD Million)
Table 8 Saudi Arabia Cell and Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 9 Kuwait Cell and Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 10 Kuwait Cell and Gene Therapy CDMO Market estimates and forecasts, by product, 2021-2033 (USD Million)
Table 11 Kuwait Cell and Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 12 UAE Cell and Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 13 UAE Cell and Gene Therapy CDMO Market estimates and forecasts, by product, 2021-2033 (USD Million)
Table 14 UAE Cell and Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 15 Oman Cell and Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 16 Oman Cell and Gene Therapy CDMO Market estimates and forecasts, by product, 2021-2033 (USD Million)
Table 17 Oman Cell and Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
Table 18 Qatar Cell and Gene Therapy CDMO Market estimates and forecasts, by phase, 2021-2033 (USD Million)
Table 19 Qatar Cell and Gene Therapy CDMO Market estimates and forecasts, by product, 2021-2033 (USD Million)
Table 20 Qatar Cell and Gene Therapy CDMO Market estimates and forecasts, by Indication, 2021-2033 (USD Million)
List of Figures
Figure 1 Middle East Cell and Gene Therapy CDMO Market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Market formulation & validation
Figure 7 Commodity flow analysis
Figure 8 Value-Chain-Based Sizing & Forecasting
Figure 9 QFD model sizing & forecasting
Figure 10 Bottom-up approach
Figure 11 Market snapshot
Figure 12 Segment snapshot
Figure 13 Segment snapshot
Figure 14 Segment snapshot
Figure 15 Competitive landscape snapshot
Figure 16 Parent market outlook, 2024 (USD Million)
Figure 17 Ancillary market outlook, 2024 (USD Million)
Figure 18 Middle East Cell and Gene Therapy CDMO Market dynamics
Figure 19 Total R&D drug pipeline size, 2021-2024
Figure 20 Total drug pipeline by development phase, 2024
Figure 21 Porter’s five forces analysis
Figure 22 PESTEL analysis
Figure 23 Middle East Cell and Gene Therapy CDMO Market Phase outlook: Segment dashboard
Figure 24 Middle East Cell and Gene Therapy CDMO Market, by Phase segment: Market share, 2025 & 2033
Figure 25 Pre-clinical market estimates and forecasts, 2021-2033 (USD Million)
Figure 26 Clinical market estimates and forecasts, 2021-2033 (USD Million)
Figure 27 Middle East Cell and Gene Therapy CDMO Market Product outlook: Segment dashboard
Figure 28 Middle East Cell and Gene Therapy CDMO Market, by Product segment: Market share, 2025 & 2033
Figure 29 Gene Therapy Gene-Modified Cell Therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 30 Ex-vivo market estimates and forecasts, 2021-2033 (USD Million)
Figure 31 in-vivo market estimates and forecasts, 2021-2033 (USD Million)
Figure 32 Gene-Modified Cell Therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 33 CAR T-cell therapies market estimates and forecasts, 2021-2033 (USD Million)
Figure 34 CAR-NK cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 35 TCR-T cell therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 36 Others market estimates and forecasts, 2021-2033 (USD Million)
Figure 37 Cell Therapy market estimates and forecasts, 2021-2033 (USD Million)
Figure 38 Middle East Cell and Gene Therapy CDMO Market Indication outlook: Segment dashboard
Figure 39 Middle East Cell and Gene Therapy CDMO Market, by Indication segment: Market share, 2025 & 2033
Figure 40 Oncology market estimates and forecasts, 2021-2033 (USD Million)
Figure 41 Infectious Diseases market estimates and forecasts, 2021-2033 (USD Million)
Figure 42 Neurological disorders market estimates and forecasts, 2021-2033 (USD Million)
Figure 43 Rare Diseases market estimates and forecasts, 2021-2033 (USD Million)
Figure 44 Others market estimates and forecasts, 2021-2033 (USD Million)
Figure 45 Country market: Key takeaways
Figure 46 Country marketplace: Key takeaways
Figure 47 Key country dynamics
Figure 48 Saudi Arabia Cell and Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 49 Key country dynamics
Figure 50 Kuwait Cell and Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 51 Key country dynamics
Figure 52 UAE Cell and Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 53 Key country dynamics
Figure 54 Oman Cell and Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 55 Key country dynamics
Figure 56 Qatar Cell and Gene Therapy CDMO Market estimates and forecasts, 2021-2033 (USD Million)
Figure 57 Market participant categorization
Figure 58 Heat map analysis

Companies Mentioned

The companies profiled in this Middle East Cell and Gene Therapy CDMO market report include:
  • Porton Pharma Solutions, Ltd. (Porton Advanced)
  • WuXi AppTec
  • Thermo Fisher Scientific, Inc.
  • Charles River Laboratories
  • Lonza
  • AGC Biologics
  • Catalent
  • Samsung Biologics
  • OmniaBio
  • Rentschler Biopharma SE

Table Information

Report AttributeDetails
No. of Pages150
PublishedOctober 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 55.68 Million
Forecasted Market Value ( USD ) by 2033 $ 184.18 Million
Compound Annual Growth Rate14.2%
Regions CoveredMiddle East
No. of Companies Mentioned11

Related Topics

Related Reports

Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), Indication (Oncology, Infectious Diseases), and Region with Growth Forecasts, 2025-2033 - Product Image

Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy), Indication (Oncology, Infectious Diseases), and Region with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), Indication (Oncology, Infectious Diseases), and Growth Forecasts, 2025-2033 - Product Image

U.S. Cell and Gene Therapy CDMO Market Size, Share & Trends Analysis Report by Phase (Pre-clinical, Clinical), Product (Gene Therapy, Cell Therapy, Gene-Modified Cell Therapy), Indication (Oncology, Infectious Diseases), and Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033 - Product Image

Cell and Gene Therapy Biomanufacturing CDMO Market - Focused on AAV - A Global and Regional Analysis: Focus on Phase of Development, Workflow, Indication, Culture Type, and Region - Analysis and Forecast, 2023-2033

  • Report
  • 336 Pages
  • Global
From
U.S. Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report by Product (Biologics, Biosimilar), Service (Contract Manufacturing, Contract Development), Source, End Use, and Country with Growth Forecasts, 2025-2033 - Product Image

U.S. Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report by Product (Biologics, Biosimilar), Service (Contract Manufacturing, Contract Development), Source, End Use, and Country with Growth Forecasts, 2025-2033

  • Report
  • 120 Pages
  • United States
From
Biologics Contract Development and Manufacturing Organization Market Forecast to 2033 - Product Image

Biologics Contract Development and Manufacturing Organization Market Forecast to 2033

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.